SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on LinkedIn or X.DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at NobleCon20, Noble Capital Markets' 20th Annual Emerging Growth Equity Conference, on Wednesday, December 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held in Boca Raton, Fla.
丹佛，2024年11月26日（環球新聞社）-- SeaStar 醫療控股公司（納斯達克：ICU）是一家處於商業階段的醫療器械公司，正在開發專有解決方案，以減少超炎症對重要器官的影響。宣佈管理層將於12月4日星期三下午12:00（東部時間9:00太平洋時間）在Noble Capital Markets第20屆新興成長股權會議NobleCon20上進行公司概況介紹。該會議將於佛羅里達州博卡拉頓舉行。
A webcast of the presentation will be available beginning December 5 on the Company website and will be archived for 90 days.
演示的網絡視頻將於12月5日開始在公司網站上提供，並將存檔90天。
About SeaStar Medical
關於SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on LinkedIn or X.
SeaStar Medical是一家商業化階段的醫療科技公司，正在重新定義體外療法如何減少對重要器官的過度炎症的後果。 SeaStar Medical的新穎技術依靠科學和創新爲危重病患者提供挽救生命的解決方案。該公司正在開發和商業化細胞定向的體外療法，以靶向驅動全身性炎症的效應細胞，導致直接組織損傷，並分泌一系列促炎性細胞因子，以啓動和傳播不平衡的免疫反應。有關更多信息，請訪問。 或訪問我們的LinkedIn主頁或X.
Contact:
聯繫方式：
Alliance Advisors IR
Jody Cain
(310) 691-7100
Jcain@allianceadvisors.com
聯盟顧問IR
Jody Cain
(310) 691-7100
Jcain@allianceadvisors.com
# # #
# # #
